Good news! Chengdu Weikang Biology's "First Prize" in 2022 has been won!
At the 2022 "Rongbu Cup" High-level Talent Innovation and Entrepreneurship Competition Biomedical Industry Ecological Integration Invitational Competition held yesterday, Weikang Bio's participating project "Domestic First Microfluidic POCT Full Scene Solution" stood out from dozens of excellent projects at home and abroad selected at all levels, and was unanimously recognized by 8 senior investor judges, ranking second with obvious advantages.
The 2022 "Rongbu Cup" High-level Talent Innovation and Entrepreneurship Competition is hosted by the Office of The Talent Work Leading Group of Chengdu City, undertaken by Chengdu Industrial Group, various districts (cities) and counties, and co-organized by more than 20 municipal departments and units. With the theme of "Better Chengdu, Better You", the competition aims to promote technical exchanges, strengthen creative collisions, accurately match resources, and help the development of talent projects. In the competition, through the 6-minute project roadshow and 2-minute judges' Q&A, Weikang Bio's project "Domestic First Microfluidic POCT Full-Scene Solution" won the unanimous praise of 8 judges, and more judges said: "For Weikang's project, we have conducted understanding and market research, and after comparison, we also feel that technology and products are indeed very advantageous!" ”
What impressed the judges was not only the comprehensive product layout, a number of global exclusive technologies, the outstanding and mature team and the high-speed industrialization efficiency; Chengdu Weikang Bio's "DISKFLU Disc Microfluidic Immuno-Immunobiology Diagnosis Platform" with a new underlying technology and a new design idea, so that the products presented "earth-shaking" changes, and finally comprehensively surpassed European and American products, which can perfectly meet the harsh requirements of Chinese clinical departments for POCT, so that the judges are full of expectations for it.
Take the five joint examinations of heart and lung as an example:
1. One sample is added, and the results of five chest pain markers are obtained at the same time in 15 minutes;
2. Ultrasensitivity troponin detection, which was realized in joint examination for the first time;
3. Whole blood dosing, centrifugation and separation of serum, no blood cell interference, more accurate detection;
4. Disc-type microfluidic control technology, multiple joint inspections do not interfere with each other, and the analysis performance indicators are consistent with single detection;
5. Patented ultra-low temperature inkjet lyophilization technology, the reagent chip can be stored at room temperature for 1 year, without cold chain.
In the five joint examinations of heart and lung, DISKFLU disc microfluidic POCT also set a "world first".
As the most specific indicator of myocardial injury so far, the "ultrasensitivity troponin" project is known as the "gold standard" for diagnosing AMI, and it is also an insurmountable gap between traditional POCT and micro-Kang Disc microfluidic POCT: traditional POCT cannot truly achieve ultrasensitivity level troponin detection in practical operations, and the performance of index detection is greatly reduced in multi-project joint inspection. Weikang's strip and disc microfluidic POCT products can truly achieve ultrasensitivity troponin detection in daily use, and on a global scale, this is the first time that "ultrasensitivity troponin" has been realized in multi-project joint inspection.
In 2021, Chengdu Weikang Bio has obtained 13 Class II medical device product registration certificates in one go, including 9 Class II testing project registration certificates and a variety of strip microfluidic detectors in two categories: inflammation and myocardium. More than 60 testing items such as "eight preoperative items", "seven items of gastrointestinal tract", "eight items of heart and lung", "four items of respiratory tract", "alpha function" and liver fibrosis and emergency obstetrics, and maternal and child health will also be registered and certified in recent years. It is worth noting that the immunodiagnostic reagents of Chengdu Weikang Bio all use the national exclusive methodology: "microfluidic time-resolved immunofluorescence method", which is understood to be much more accurate than traditional fluorescence, and its performance is completely comparable to the world's top large-scale chemiluminescent products.
In addition to good performance, new products, many projects, product cost is also the most critical factor in whether IVD products can successfully seize market share, and the design cost of Microfluidic chip of Chengdu Weikang Bio is only one-fifth to one-eighth of the domestic and foreign competitors, it can be said that it will take advantage of the market competition, so as early as the DISKFLU disc microfluidic POCT has not yet obtained the certificate, there have been agents in many provinces who have taken the initiative to seek cooperation and hope to represent Chengdu Weikang's products, I believe that since the official opening of sales in early 2022, The DISKFLU disc-type microfluidic joint inspection platform will soon appear in major hospitals across the country, which is unique in the clinical department POCT market.
Soon, Chengdu Weikang Bio will represent the biomedical industry in the final finals of the 2022 "Rong Drift Cup" industry-wide and all-field projects to compete for the final prize. In the first month of 2022, Weikang ushered in the "opening red" to win the first prize of the new year, I believe that in 2022, Weikang will be able to have a long and prosperous life, successfully complete the development goals, and enter a new stage of industrialization development. Let's wait and see!